Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
复制标题
DOI：
10.1038/s41391-021-00463-9
复制
发表时间：
2022-09
影响因子：
4.8
通讯作者：
Freedland, Stephen J.
中科院分区：
文献类型：
--
作者：
George, Daniel J.;Ramaswamy, Krishnan;Huang, Ahong;Russell, David;Mardekian, Jack;Schultz, Neil M.;Janjan, Nora;Freedland, Stephen J.
黑人男性比白色男性更容易被诊断出患有侵袭性前列腺癌（PC）并死于PC。然而，在临床试验中接受某些药物治疗时，患有转移性去势抵抗性PC（mCRPC）的黑人男性的总生存期（OS）长于白色男性。我们分析了来自退伍军人健康管理局（VHA）数据库的声明数据，以评价接受enzalutamide或阿比特龙（新型激素治疗[NHT]）治疗化疗初治mCRPC的黑人和白色男性的OS。根据2014年4月至2017年3月期间的诊断代码、手术/药物去势证据和去势后Enzalutamide或阿比特龙处方声明，在VHA数据库中识别年龄≥18岁的mCRPC患者。考克斯模型评估种族和OS之间的关联。对整个人群和基于NHT后接受的治疗类型（如果有的话）的亚组进行未校正和多变量分析。总共确定了2910例患者（787例黑人，平均71.7岁; 2123例白色，平均74.0岁）。黑人和白人的中位随访时间分别为19.0和18.7个月。与白色男性相比，黑人男性的生存率更高：在未校正和多变量模型中，风险比（95%CI）分别为0.89（0.790-0.996; P = 0.044）和0.67（0.592-0.758; P < 0.0001）。无论后续治疗如何（包括没有后续治疗），黑人男性的OS均比白色男性的OS在统计学上显着更长。在VHA中，启动NHT的未经化疗mCRPC黑人男性患者的结局可能优于接受类似治疗的白色男性患者。
Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than white men when treated with certain agents in clinical trials. We analyzed claims data from the Veterans Health Administration (VHA) database to evaluate OS in black and white men treated with enzalutamide or abiraterone (novel hormonal therapy [NHT]) for chemotherapy-naïve mCRPC. Patients with mCRPC aged ≥18 years were identified in the VHA database by diagnosis codes, evidence of surgical/medical castration, and a prescription claim for enzalutamide or abiraterone after castration from April 2014–March 2017. Cox models assessed associations between race and OS. Unadjusted and multivariable analyses were performed on the entire population and subsets based on the type of therapy received (if any) after NHT. In total, 2910 patients were identified (787 black, mean 71.7 years; 2123 white, mean 74.0 years). Median follow-up was 19.0 and 18.7 months in blacks and whites, respectively. Black men had better survival versus white men: hazard ratios (95% CIs) were 0.89 (0.790–0.996; P = 0.044) and 0.67 (0.592–0.758; P < 0.0001) in the unadjusted and multivariable models, respectively. Statistically significantly longer OS was seen in black versus white men regardless of subsequent treatment, including no subsequent treatment. In the VHA, black men with chemotherapy-naïve mCRPC initiating NHT may have better outcomes than similarly treated white men.
登录
查看更多内容
影响因子：
3.5
作者：
Rebbeck, Timothy R.
通讯作者：
Rebbeck, Timothy R.
影响因子：
10.3
作者：
Unger, Joseph M.;Barlow, William E.;Hershman, Dawn L.
通讯作者：
Hershman, Dawn L.
影响因子：
28.4
作者：
Dess, Robert T.;Hartman, Holly E.;Spratt, Daniel E.
通讯作者：
Spratt, Daniel E.
影响因子：
51.1
作者：
Ryan, Charles J.;Smith, Matthew R.;Rathkopf, Dana E.
通讯作者：
Rathkopf, Dana E.
影响因子：
6.2
作者：
Tsodikov A;Gulati R;de Carvalho TM;Heijnsdijk EAM;Hunter-Merrill RA;Mariotto AB;de Koning HJ;Etzioni R
通讯作者：
Etzioni R